BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1840347)

  • 1. Clinical significance of correction of serum beta 2-microglobulin levels for serum creatinine in multiple myeloma.
    Scudla V; Vavrdová V; Budíková M; Indrák K
    Acta Univ Palacki Olomuc Fac Med; 1991; 131():257-64. PubMed ID: 1840347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
    Avilés A; Zepeda G; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
    Rev Invest Clin; 1992; 44(2):215-20. PubMed ID: 1439309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Serum beta 2-microglobulin in multiple myeloma. I. Relation to selected indicators, clinical stage and disease prognosis].
    Scudla V; Budíková M; Fischerová E; Raska I; Vavrdová V
    Vnitr Lek; 1991 Apr; 37(4):342-51. PubMed ID: 2053304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical usefulness of serum beta2-microglobulin determination in patients with multiple myeloma].
    Kraj M; Maj S; Pogłód R; Rostkowska J
    Acta Haematol Pol; 1989; 20(2):140-51. PubMed ID: 2700533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stratification of multiple myeloma according to serum beta 2-microglobulin and serum albumin levels.
    Scudla V; Budíková M; Fischerová E; Zadrazil J; Indrák K
    Acta Univ Palacki Olomuc Fac Med; 1991; 130():201-12. PubMed ID: 1838869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A study of the significance of serum beta 2-microglobulin levels in patients with multiple myeloma--analyzes as a marker of renal dysfunction and as a marker of tumor cell mass].
    Nishinarita S; Shimada H; Suzuki R; Kishigami Y; Sawada U; Horie T
    Rinsho Ketsueki; 1996 Mar; 37(3):201-7. PubMed ID: 8727343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
    Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
    Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
    Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
    Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Serum ferritin and beta-2-microglobulin in multiple myeloma].
    Linkesch W; Ludwig H
    Acta Med Austriaca; 1982; 9(5-6):227-31. PubMed ID: 6187172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients].
    Lubo-Lesnichenko IF; Bessmel'tsev SS; Abdulkadyrov KM; Blinov MN; Stel'mashenko LV
    Ter Arkh; 1996; 68(10):28-31. PubMed ID: 9026938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Serum beta 2-microglobulin in multiple myeloma. II. Its significance in monitoring the disease].
    Scudla V; Budíková M; Fischerová E; Raska I; Vavrdová V
    Vnitr Lek; 1991 May; 37(5):479-87. PubMed ID: 1842146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum ferritin and beta 2-microglobulin in patients with multiple myeloma.
    Linkesch W; Ludwig H
    Cancer Detect Prev; 1983; 6(1-2):297-301. PubMed ID: 6192921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Serum beta-2-microglobulin in multiple myeloma. Practical value].
    Bataille R; Magub M; Sany J; Donadio D; Izarn P; Grenier J; Suquet P
    Rev Rhum Mal Osteoartic; 1981 Mar; 48(3):235-40. PubMed ID: 6164091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
    Kyrtsonis MC; Vassilakopoulos TP; Siakantaris MP; Kokoris SI; Gribabis DA; Dimopoulou MN; Angelopoulou MK; Pangalis GA
    Eur J Haematol; 2004 Apr; 72(4):252-8. PubMed ID: 15089762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta-2-microglobulin in multiple myeloma.
    Musarurwa C; Matarira HT
    Cent Afr J Med; 2004; 50(1-2):19-20. PubMed ID: 15490720
    [No Abstract]   [Full Text] [Related]  

  • 16. [The significance of lactate dehydrogenase and beta 2-microglobulin levels for the assessment of the prognosis and choice of therapy in multiple myeloma].
    Iakovleva SV; Andreeva NE; Izgorodin AS
    Ter Arkh; 1995; 67(7):35-9. PubMed ID: 7482303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor load in patients with multiple myeloma: β2-microglobulin levels versus whole-body MRI.
    D'Anastasi M; Notohamiprodjo M; Schmidt GP; Dürr HR; Reiser MF; Baur-Melnyk A
    AJR Am J Roentgenol; 2014 Oct; 203(4):854-62. PubMed ID: 25247952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Soluble interleukin-6 receptors in the serum in multiple myeloma].
    Scudla V; Kubalová D; Bacovský J; Lukes J; Vavrdová V
    Cas Lek Cesk; 1996 Nov; 135(22):719-22. PubMed ID: 8998823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unexpected normal serum beta-microglobulin (B2M) levels in multiple myeloma.
    Bataille R; Grenier J; Sany J
    Anticancer Res; 1987; 7(3 Pt B):513-5. PubMed ID: 3307602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Assay of serum beta 2-microglobulin in patients with malignant hematologic diseases and its clinical significance].
    Zhong M; Liu W
    Hunan Yi Ke Da Xue Xue Bao; 1997; 22(3):277-8. PubMed ID: 9868137
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.